Patent intelligence · US
US 10646443
Sustained release olanzapine formulations
Sustained release olanzapine formulations
Patent details — US 10646443
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 12, 2020
- Expiration
- May 7, 2040
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Claims
- 58
- CPC classes
- A61K, A61K31/551, A61K31/5513, A61K47/34
Quick answer
US 10646443 (Sustained release olanzapine formulations) is held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH. Status: granted. Granted May 12, 2020. Expires May 7, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Grant date
- Expiration
- Claims
- 58
- CPC classes
- A61K, A61K31/551, A61K31/5513, A61K47/34, A61K9/0019, A61K9/146
More from TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 10646443?
US 10646443 (Sustained release olanzapine formulations) is held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH. Status: granted. Granted May 12, 2020. Expires May 7, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10646443?
TEVA PHARMACEUTICALS INTERNATIONAL GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 10646443 expire?
Our index shows an expiration date of May 7, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.